A carregar...
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...
Na minha lista:
| Publicado no: | J Bone Miner Res |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/ https://ncbi.nlm.nih.gov/pubmed/31411768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|